{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:44:36Z","timestamp":1789469076647,"version":"build-2803163510"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01048-9","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:46:29Z","timestamp":1782135989000},"page":"1027-1043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-3671","authenticated-orcid":false,"given":"Francisco Jos\u00e9","family":"Navarro-Trivi\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384:1136\u201343. https:\/\/doi.org\/10.1056\/NEJMra2023911.","journal-title":"N Engl J Med"},{"key":"1048_CR2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80:390\u2013401. https:\/\/doi.org\/10.1016\/j.jaad.2018.09.035.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaad.2023.04.052","volume":"89","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson B, Abuabara K, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023;89:519\u201328. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.052.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"P Lio","year":"2020","unstructured":"Lio P, Wollenberg A, Thyssen J, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19:943\u20138. https:\/\/doi.org\/10.36849\/JDD.2020.5422.","journal-title":"J Drugs Dermatol"},{"key":"1048_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1114321","author":"H Chu","year":"2023","unstructured":"Chu H, Kim SM, Zhang K, et al. Head and neck dermatitis is exacerbated by Malassezia furfur colonization, skin barrier disruption, and immune dysregulation. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1114321.","journal-title":"Front Immunol"},{"key":"1048_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/joim.13235","volume":"290","author":"A Sch\u00e4bitz","year":"2021","unstructured":"Sch\u00e4bitz A, Eyerich K, Garzorz-Stark N. So close, and yet so far away: the dichotomy of the specific immune response and inflammation in psoriasis and atopic sermatitis. J Intern Med. 2021;290:27\u201339. https:\/\/doi.org\/10.1111\/joim.13235.","journal-title":"J Intern Med"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40257-021-00646-z","volume":"23","author":"S Muzumdar","year":"2022","unstructured":"Muzumdar S, Skudalski L, Sharp K, et al. Dupilumab facial redness\/dupilumab facial dermatitis: a guide for clinicians. Am J Clin Dermatol. 2022;23:61\u20137. https:\/\/doi.org\/10.1007\/s40257-021-00646-z.","journal-title":"Am J Clin Dermatol"},{"key":"1048_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1346-8138.16764","volume":"50","author":"M Napolitano","year":"2023","unstructured":"Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study. J Dermatol. 2023;50:880\u20137. https:\/\/doi.org\/10.1111\/1346-8138.16764.","journal-title":"J Dermatol"},{"key":"1048_CR9","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84:1339\u201347. https:\/\/doi.org\/10.1016\/j.jaad.2021.01.012.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14712598.2023.2224499","volume":"23","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Peris K, Chiricozzi A. Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023;23:575\u20137. https:\/\/doi.org\/10.1080\/14712598.2023.2224499.","journal-title":"Expert Opin Biol Ther"},{"key":"1048_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jdermsci.2021.04.007","volume":"102","author":"T Luger","year":"2021","unstructured":"Luger T, Amagai M, Dreno B, et al. Atopic dermatitis: role of the skin barrier, environment, microbiome, and therapeutic agents. J Dermatol Sci. 2021;102:142\u201357. https:\/\/doi.org\/10.1016\/j.jdermsci.2021.04.007.","journal-title":"J Dermatol Sci"},{"key":"1048_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jid.2024.03.006","volume":"144","author":"M Schmuth","year":"2024","unstructured":"Schmuth M, Eckmann S, Moosbrugger-Martinz V, et al. Skin barrier in atopic dermatitis. J Investig Dermatol. 2024;144:989-1000.e1. https:\/\/doi.org\/10.1016\/j.jid.2024.03.006.","journal-title":"J Investig Dermatol"},{"key":"1048_CR13","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.3390\/ijms21155382","volume":"21","author":"M Furue","year":"2020","unstructured":"Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci. 2020;21:5382. https:\/\/doi.org\/10.3390\/ijms21155382.","journal-title":"Int J Mol Sci"},{"key":"1048_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jdermsci.2025.04.001","volume":"118","author":"T Sakai","year":"2025","unstructured":"Sakai T, Hatano Y. Stratum corneum PH and ceramides: key regulators and biomarkers of skin barrier function in atopic dermatitis. J Dermatol Sci. 2025;118:51\u20137. https:\/\/doi.org\/10.1016\/j.jdermsci.2025.04.001.","journal-title":"J Dermatol Sci"},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2133.2009.09142.x","volume":"161","author":"R Voegeli","year":"2009","unstructured":"Voegeli R, Rawlings AV, Breternitz M, et al. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br J Dermatol. 2009;161:70\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09142.x.","journal-title":"Br J Dermatol"},{"key":"1048_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2022.06.004","volume":"107","author":"S Morizane","year":"2022","unstructured":"Morizane S, Sunagawa K, Nomura H, et al. Aberrant serine protease activities in atopic dermatitis. J Dermatol Sci. 2022;107:2\u20137. https:\/\/doi.org\/10.1016\/j.jdermsci.2022.06.004.","journal-title":"J Dermatol Sci"},{"key":"1048_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/ijms21030913","volume":"21","author":"H Nomura","year":"2020","unstructured":"Nomura H, Suganuma M, Takeichi T, et al. Multifaceted analyses of epidermal serine protease activity in patients with atopic dermatitis. Int J Mol Sci. 2020;21:913. https:\/\/doi.org\/10.3390\/ijms21030913.","journal-title":"Int J Mol Sci"},{"key":"1048_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1239251","author":"Y Hatano","year":"2023","unstructured":"Hatano Y, Elias PM. \u201cOutside-to-inside\u201d, \u201cinside-to-outside\u201d, and \u201cintrinsic\u201d endogenous pathogenic mechanisms in atopic dermatitis: keratinocytes as the key functional cells involved in both permeability barrier dysfunction and immunological alterations. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1239251.","journal-title":"Front Immunol"},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3390\/ijms23042121","volume":"23","author":"P Pavel","year":"2022","unstructured":"Pavel P, Blunder S, Moosbrugger-Martinz V, et al. Atopic dermatitis: the fate of the fat. Int J Mol Sci. 2022;23:2121. https:\/\/doi.org\/10.3390\/ijms23042121.","journal-title":"Int J Mol Sci"},{"key":"1048_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2500\/aap.2023.44.230010","volume":"44","author":"S Al","year":"2023","unstructured":"Al S, Asilsoy S, Atay O, et al. Transepidermal water loss in allergic diseases. Allergy Asthma Proc. 2023;44:186\u201392. https:\/\/doi.org\/10.2500\/aap.2023.44.230010.","journal-title":"Allergy Asthma Proc"},{"key":"1048_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/jcm10020359","volume":"10","author":"T Montero-Vilchez","year":"2021","unstructured":"Montero-Vilchez T, Segura-Fern\u00e1ndez-Nogueras M-V, P\u00e9rez-Rodr\u00edguez I, et al. Skin barrier function in psoriasis and atopic dermatitis: transepidermal water loss and temperature as useful tools to assess disease severity. J Clin Med. 2021;10:359. https:\/\/doi.org\/10.3390\/jcm10020359.","journal-title":"J Clin Med"},{"key":"1048_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.jid.2017.11.040","volume":"138","author":"K Yamaga","year":"2018","unstructured":"Yamaga K, Murota H, Tamura A, et al. Claudin-3 loss causes leakage of sweat from the sweat gland toc ontribute to the pathogenesis of atopic dermatitis. J Investig Dermatol. 2018;138:1279\u201387. https:\/\/doi.org\/10.1016\/j.jid.2017.11.040.","journal-title":"J Investig Dermatol"},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/bjd.18781","volume":"183","author":"AJ Hendricks","year":"2020","unstructured":"Hendricks AJ, Eichenfield LF, Shi VY. The impact of airborne pollution on atopic dermatitis: a literature review. Br J Dermatol. 2020;183:16\u201323. https:\/\/doi.org\/10.1111\/bjd.18781.","journal-title":"Br J Dermatol"},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"9888","DOI":"10.3390\/ijms25189888","volume":"25","author":"K Paik","year":"2024","unstructured":"Paik K, Na J-I, Huh C-H, Shin J-W. Particulate matter and its molecular effects on skin: implications for various skin diseases. Int J Mol Sci. 2024;25:9888. https:\/\/doi.org\/10.3390\/ijms25189888.","journal-title":"Int J Mol Sci"},{"key":"1048_CR25","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.3390\/ijerph20032526","volume":"20","author":"RP Fadadu","year":"2023","unstructured":"Fadadu RP, Abuabara K, Balmes JR, et al. Air pollution and atopic dermatitis, from molecular mechanisms to population-level evidence: a review. Int J Environ Res Public Health. 2023;20:2526. https:\/\/doi.org\/10.3390\/ijerph20032526.","journal-title":"Int J Environ Res Public Health"},{"key":"1048_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2024.116429","volume":"278","author":"X Gu","year":"2024","unstructured":"Gu X, Li Z, Su J. Air pollution and skin diseases: a comprehensive evaluation of the associated mechanism. Ecotoxicol Environ Saf. 2024;278:116429. https:\/\/doi.org\/10.1016\/j.ecoenv.2024.116429.","journal-title":"Ecotoxicol Environ Saf"},{"key":"1048_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14840","author":"R Abolhasani","year":"2021","unstructured":"Abolhasani R, Araghi F, Tabary M, Aryannejad A, Mashinchi B, Robati RM. The impact of air pollution on skin and related disorders: a comprehensive review. Dermatol Ther. 2021. https:\/\/doi.org\/10.1111\/dth.14840.","journal-title":"Dermatol Ther"},{"key":"1048_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1124\/molpharm.122.000627","volume":"103","author":"C de Almeila Freitas Accioli","year":"2023","unstructured":"de Almeila Freitas Accioli C, da Silva MS, Santos BAMC, et al. Aryl hydrocarbon receptor as a therapeutical target of environmentally induced skin conditions. Mol Pharmacol. 2023;103:255\u201365. https:\/\/doi.org\/10.1124\/molpharm.122.000627.","journal-title":"Mol Pharmacol"},{"key":"1048_CR29","doi-asserted-by":"publisher","first-page":"9412","DOI":"10.3390\/ijms21249412","volume":"21","author":"YH Vu","year":"2020","unstructured":"Vu YH, Hashimoto-Hachiya A, Takemura M, et al. IL-24 negatively regulates keratinocyte differentiation induced by tapinarof, an aryl hydrocarbon receptor modulator: implication in the treatment of atopic dermatitis. Int J Mol Sci. 2020;21:9412. https:\/\/doi.org\/10.3390\/ijms21249412.","journal-title":"Int J Mol Sci"},{"key":"1048_CR30","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.3390\/ijms20215424","volume":"20","author":"M Furue","year":"2019","unstructured":"Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20:5424. https:\/\/doi.org\/10.3390\/ijms20215424.","journal-title":"Int J Mol Sci"},{"key":"1048_CR31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00403-024-03448-5","volume":"316","author":"S Boonpethkaew","year":"2024","unstructured":"Boonpethkaew S, Charoensuksira S, Meephansan J, et al. The influence of air pollution on skin microbiome: a link to skin barrier dysfunction. Arch Dermatol Res. 2024;316:710. https:\/\/doi.org\/10.1007\/s00403-024-03448-5.","journal-title":"Arch Dermatol Res"},{"key":"1048_CR32","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/exd.14622","volume":"31","author":"C Chueachavalit","year":"2022","unstructured":"Chueachavalit C, Meephansan J, Payungporn S, et al. Comparison of Malassezia spp. colonization between human skin exposed to high- and low-ambient air pollution. Exp Dermatol. 2022;31:1454\u201361. https:\/\/doi.org\/10.1111\/exd.14622.","journal-title":"Exp Dermatol"},{"key":"1048_CR33","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/biomedicines13102458","volume":"13","author":"FJ Navarro Trivi\u00f1o","year":"2025","unstructured":"Navarro Trivi\u00f1o FJ, Velasco Amador JP, Rivera RI. Seborrheic dermatitis revisited: pathophysiology, diagnosis, and emerging therapies: a narrative review. Biomedicines. 2025;13:2458. https:\/\/doi.org\/10.3390\/biomedicines13102458.","journal-title":"Biomedicines."},{"key":"1048_CR34","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.3390\/ijms24043950","volume":"24","author":"P Smythe","year":"2023","unstructured":"Smythe P, Wilkinson HN. The skin microbiome: current landscape and future opportunities. Int J Mol Sci. 2023;24:3950. https:\/\/doi.org\/10.3390\/ijms24043950.","journal-title":"Int J Mol Sci"},{"key":"1048_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1480257","author":"Z Wang","year":"2024","unstructured":"Wang Z, H\u00fclp\u00fcsch C, Traidl-Hoffmann C, et al. Understanding the role of Staphylococcus aureus in atopic dermatitis: strain diversity, microevolution, and prophage influences. Front Med (Lausanne). 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1480257.","journal-title":"Front Med (Lausanne)."},{"key":"1048_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.tim.2017.11.008","volume":"26","author":"JA Geoghegan","year":"2018","unstructured":"Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol. 2018;26:484\u201397. https:\/\/doi.org\/10.1016\/j.tim.2017.11.008.","journal-title":"Trends Microbiol"},{"key":"1048_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2025.12.1009","volume":"157","author":"C Chehadeh","year":"2026","unstructured":"Chehadeh C, Nakatsuji T, Gallo RL. Staphylococcus aureus in atopic dermatitis: how a common bacterium exploits and drives disease. J Allergy Clin Immuno. 2026;157:551\u20137. https:\/\/doi.org\/10.1016\/j.jaci.2025.12.1009.","journal-title":"J Allergy Clin Immuno"},{"key":"1048_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/myc.70014","author":"J Sasikumar","year":"2025","unstructured":"Sasikumar J, Ebrahim RA, Das SP. Diverse colonisation and disease associations of the human commensal Malassezia: our body\u2019s secret tenant. Mycoses. 2025. https:\/\/doi.org\/10.1111\/myc.70014.","journal-title":"Mycoses"},{"key":"1048_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2008.07.058","volume":"60","author":"K Darabi","year":"2009","unstructured":"Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60:25\u2013136. https:\/\/doi.org\/10.1016\/j.jaad.2008.07.058.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15108","author":"H See Tow","year":"2024","unstructured":"See Tow H, Yew YW. Malassezia specific IgE in head and neck dermatitis of eczema: a systematic review and meta-analysis. Exp Dermatol. 2024. https:\/\/doi.org\/10.1111\/exd.15108.","journal-title":"Exp Dermatol"},{"key":"1048_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaci.2011.02.043","volume":"128","author":"H Balaji","year":"2011","unstructured":"Balaji H, Heratizadeh A, Wichmann K, et al. Malassezia sympodialis thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis. J Allergy Clin Immunol. 2011;128:92-9.e4. https:\/\/doi.org\/10.1016\/j.jaci.2011.02.043.","journal-title":"J Allergy Clin Immunol"},{"key":"1048_CR42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/CCID.S517415","volume":"18","author":"Z Wu","year":"2025","unstructured":"Wu Z, Yu H, Chen Z, Liu W, Xia P. Malassezia globosa aggravates atopic dermatitis by influencing the Th1\/Th2 related cytokines in mouse models. Clin Cosmet Investig Dermatol. 2025;18:837\u201344. https:\/\/doi.org\/10.2147\/CCID.S517415.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1048_CR43","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jid.2020.07.027","volume":"141","author":"F Zeng","year":"2021","unstructured":"Zeng F, Chen H, Chen L, et al. An autocrine circuit of IL-33 in keratinocytes is involved in the progression of psoriasis. J Investig Dermatol. 2021;141:596\u2013606. https:\/\/doi.org\/10.1016\/j.jid.2020.07.027.","journal-title":"J Investig Dermatol"},{"key":"1048_CR44","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/infdis\/jiab194","volume":"223","author":"H Miyachi","year":"2021","unstructured":"Miyachi H, Wakabayashi S, Sugihira T, et al. Keratinocyte IL-36 receptor\/MyD88 signaling mediates Malassezia-induced IL-17-dependent skin inflammation. J Infect Dis. 2021;223:1753\u201365. https:\/\/doi.org\/10.1093\/infdis\/jiab194.","journal-title":"J Infect Dis"},{"key":"1048_CR45","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/all.15569","volume":"78","author":"H Yin","year":"2023","unstructured":"Yin H, Qiu Z, Zhu R, et al. Dysregulated lipidome of sebum in patients with atopic dermatitis. Allergy. 2023;78:1524\u201337. https:\/\/doi.org\/10.1111\/all.15569.","journal-title":"Allergy"},{"key":"1048_CR46","doi-asserted-by":"publisher","first-page":"8857","DOI":"10.3390\/ijms26188857","volume":"26","author":"I Fer\u010dek","year":"2025","unstructured":"Fer\u010dek I, Ozreti\u0107 P, Zanze L, et al. The role of skin microbiota in facial dermatoses and related factors: a narrative review. Int J Mol Sci. 2025;26:8857. https:\/\/doi.org\/10.3390\/ijms26188857.","journal-title":"Int J Mol Sci"},{"key":"1048_CR47","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1365-2133.2012.11014.x","volume":"167","author":"C Vlachos","year":"2012","unstructured":"Vlachos C, Schulte BM, Magiatis P, et al. Malassezia-derived indoles activate the aryl hydrocarbon receptor and inhibit Toll-like receptor-induced maturation in monocyte-derived dendritic cells. Br J Dermatol. 2012;167:496\u2013505. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11014.x.","journal-title":"Br J Dermatol"},{"key":"1048_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/pde.14437","volume":"38","author":"A Guglielmo","year":"2021","unstructured":"Guglielmo A, Sechi A, Patrizi A, et al. Head and neck dermatitis, a subtype of atopic dermatitis induced by Malassezia spp.: clinical aspects and treatment outcomes in adolescent and adult patients. Pediatr Dermatol. 2021;38:109\u201314. https:\/\/doi.org\/10.1111\/pde.14437.","journal-title":"Pediatr Dermatol"},{"key":"1048_CR49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","volume":"48","author":"E Guttman-Yassky","year":"2017","unstructured":"Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum. Curr Opin Immunol. 2017;48:68\u201373. https:\/\/doi.org\/10.1016\/j.coi.2017.08.008.","journal-title":"Curr Opin Immunol"},{"key":"1048_CR50","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/s41467-025-59340-x","volume":"16","author":"A Fukushima-Nomura","year":"2025","unstructured":"Fukushima-Nomura A, Kawasaki H, Yashiro K, et al. An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis. Nat Commun. 2025;16:4981. https:\/\/doi.org\/10.1038\/s41467-025-59340-x.","journal-title":"Nat Commun"},{"key":"1048_CR51","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3390\/biom15111500","volume":"15","author":"H Chai","year":"2025","unstructured":"Chai H, Siu WS, Ma H, et al. Understanding atopic dermatitis: pathophysiology and management strategies. Biomolecules. 2025;15:1500. https:\/\/doi.org\/10.3390\/biom15111500.","journal-title":"Biomolecules"},{"key":"1048_CR52","doi-asserted-by":"publisher","first-page":"11804","DOI":"10.26355\/eurrev_202011_23837","volume":"24","author":"RT Hern\u00e1ndez-Rodr\u00edguez","year":"2020","unstructured":"Hern\u00e1ndez-Rodr\u00edguez RT, Amezcua-Guerra LM. The potential role of microRNAs as biomarkers in atopic dermatitis: a systematic review. Eur Rev Med Pharmacol Sci. 2020;24:11804\u20139. https:\/\/doi.org\/10.26355\/eurrev_202011_23837.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1048_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.semcdb.2023.04.005","volume":"154","author":"S Akhtar","year":"2024","unstructured":"Akhtar S, Alsayed RKME, Ahmad F, et al. Epigenetic control of inflammation in atopic dermatitis. Semin Cell Dev Biol. 2024;154:199\u2013220. https:\/\/doi.org\/10.1016\/j.semcdb.2023.04.005.","journal-title":"Semin Cell Dev Biol"},{"key":"1048_CR54","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1111\/jcmm.15208","volume":"24","author":"X Yu","year":"2020","unstructured":"Yu X, Wang M, Li L, et al. MicroRNAs in atopic dermatitis: a systematic review. J Cell Mol Med. 2020;24:5966\u201372. https:\/\/doi.org\/10.1111\/jcmm.15208.","journal-title":"J Cell Mol Med"},{"key":"1048_CR55","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jaci.2013.11.008","volume":"133","author":"C Malmh\u00e4ll","year":"2014","unstructured":"Malmh\u00e4ll C, Alawieh S, Lu Y, Sj\u00f6strand M, Bossios A, Eldh M, et al. MicroRNA-155 is essential for TH2-mediated allergen-induced eosinophilic inflammation in the lung. J Allergy Clin Immunol. 2014;133:1429-38.e7. https:\/\/doi.org\/10.1016\/j.jaci.2013.11.008.","journal-title":"J Allergy Clin Immunol"},{"key":"1048_CR56","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.3390\/ijms26125846","volume":"26","author":"N Go\u0142uchowska","year":"2025","unstructured":"Go\u0142uchowska N, Z\u0105ber A, B\u0119dzichowska A, et al. The role of microRNA in the pathogenesis of atopic dermatitis. Int J Mol Sci. 2025;26:5846. https:\/\/doi.org\/10.3390\/ijms26125846.","journal-title":"Int J Mol Sci"},{"key":"1048_CR57","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaci.2010.05.045","volume":"126","author":"E Sonkoly","year":"2010","unstructured":"Sonkoly E, Janson P, Majuri M-L, et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol. 2010;126:581-9.e20. https:\/\/doi.org\/10.1016\/j.jaci.2010.05.045.","journal-title":"J Allergy Clin Immunol"},{"key":"1048_CR58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/cei.12624","volume":"181","author":"L Ma","year":"2015","unstructured":"Ma L, Xue H-B, Wang F, et al. MicroRNA-155 may be involved in the pathogenesis of atopic dermatitis by modulating the differentiation and function of T helper type 17 (Th17) cells. Clin Exp Immunol. 2015;181:142\u20139. https:\/\/doi.org\/10.1111\/cei.12624.","journal-title":"Clin Exp Immunol"},{"key":"1048_CR59","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/JLB.3MR0218-079R","volume":"104","author":"X Yuan","year":"2018","unstructured":"Yuan X, Berg N, Lee JW. MicroRNA MiR-223 as regulator of innate immunity. J Leukoc Biol. 2018;104:515\u201324. https:\/\/doi.org\/10.1002\/JLB.3MR0218-079R.","journal-title":"J Leukoc Biol"},{"key":"1048_CR60","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jaci.2013.06.036","volume":"133","author":"G Herberth","year":"2014","unstructured":"Herberth G, Bauer M, Gasch M, et al. Maternal and cord blood MiR-223 expression associates with prenatal tobacco smoke exposure and low regulatory T-cell numbers. J Allergy Clin Immunol. 2014;133:543-50.e4. https:\/\/doi.org\/10.1016\/j.jaci.2013.06.036.","journal-title":"J Allergy Clin Immunol"},{"key":"1048_CR61","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1111\/all.13849","volume":"74","author":"H Vaher","year":"2019","unstructured":"Vaher H, Runnel T, Urgard E, et al. MiR-10a-5p is increased in atopic dermatitis and has capacity to inhibit keratinocyte proliferation. Allergy. 2019;74:2146\u201356. https:\/\/doi.org\/10.1111\/all.13849.","journal-title":"Allergy"},{"key":"1048_CR62","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s00018-012-1124-0","volume":"69","author":"A Liston","year":"2012","unstructured":"Liston A, Papadopoulou AS, Danso-Abeam D, Dooley J. MicroRNA-29 in the adaptive immune system: setting the threshold. Cell Mol Life Sci. 2012;69:3533\u201341. https:\/\/doi.org\/10.1007\/s00018-012-1124-0.","journal-title":"Cell Mol Life Sci"},{"key":"1048_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00578","author":"R Saba","year":"2014","unstructured":"Saba R, Sorensen DL, Booth SA. MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front Immunol. 2014. https:\/\/doi.org\/10.3389\/fimmu.2014.00578.","journal-title":"Front Immunol"},{"key":"1048_CR64","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jaci.2014.05.022","volume":"134","author":"A Rebane","year":"2014","unstructured":"Rebane A, Runnel T, Aab A, et al. MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol. 2014;134:836-47.e11. https:\/\/doi.org\/10.1016\/j.jaci.2014.05.022.","journal-title":"J Allergy Clin Immunol"},{"key":"1048_CR65","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/bjd.19254","volume":"184","author":"J Nousbeck","year":"2021","unstructured":"Nousbeck J, McAleer MA, Hurault G, et al. MicroRNA analysis of childhood atopic dermatitis reveals a role for MiR-451a. Br J Dermatol. 2021;184:514\u201323. https:\/\/doi.org\/10.1111\/bjd.19254.","journal-title":"Br J Dermatol"},{"key":"1048_CR66","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/bjd.21019","volume":"186","author":"E Kozera","year":"2022","unstructured":"Kozera E, Stewart T, Gill K, et al. Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study. Br J Dermatol. 2022;186:1050\u20132. https:\/\/doi.org\/10.1111\/bjd.21019.","journal-title":"Br J Dermatol"},{"key":"1048_CR67","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15:2839. https:\/\/doi.org\/10.1038\/s41467-024-46540-0.","journal-title":"Nat Commun"},{"issue":"2","key":"1048_CR68","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/all.70060","volume":"81","author":"P D\u2019Avino","year":"2026","unstructured":"D\u2019Avino P, Kim J, Li M, et al. Distinct roles of IL-4,IL-13, and IL-22 in human skin barrier dysfunction and atopic dermatitis. Allergy. 2026;81(2):480\u201397. https:\/\/doi.org\/10.1111\/all.70060.","journal-title":"Allergy"},{"key":"1048_CR69","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.18730","volume":"183","author":"LEM Wijs","year":"2020","unstructured":"Wijs LEM, Nguyen NT, Kunkeler ACM, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183:745\u20139. https:\/\/doi.org\/10.1111\/bjd.18730.","journal-title":"Br J Dermatol"},{"key":"1048_CR70","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.jid.2023.12.018","volume":"144","author":"K Bier","year":"2024","unstructured":"Bier K, Senajova Z, Henrion F, et al. IL-26 potentiates type 2 skin inflammation in the presence of IL-1\u03b2. J Investig Dermatol. 2024;144:1544-56.e9. https:\/\/doi.org\/10.1016\/j.jid.2023.12.018.","journal-title":"J Investig Dermatol"},{"key":"1048_CR71","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2022.12.052","volume":"88","author":"K Singh","year":"2023","unstructured":"Singh K, Valido K, Swallow M, et al. Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. J Am Acad Dermatol. 2023;88:1094\u2013100. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.052.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR72","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2605426","author":"S Li","year":"2026","unstructured":"Li S, Lin J, Yang X, et al. From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases. J Dermatol Treat. 2026. https:\/\/doi.org\/10.1080\/09546634.2025.2605426.","journal-title":"J Dermatol Treat"},{"key":"1048_CR73","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/eji.201546070","volume":"46","author":"PM Cochez","year":"2016","unstructured":"Cochez PM, Michiels C, Hendrickx E, et al. AhR modulates the IL-22-producing cell proliferation\/recruitment in imiquimod-induced psoriasis mouse model. Eur J Immunol. 2016;46:1449\u201359. https:\/\/doi.org\/10.1002\/eji.201546070.","journal-title":"Eur J Immunol"},{"key":"1048_CR74","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54\u201362. https:\/\/doi.org\/10.1111\/all.13954.","journal-title":"Allergy"},{"key":"1048_CR75","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/imm.13120","volume":"158","author":"K Furue","year":"2019","unstructured":"Furue K, Ito T, Tsuji G, et al. The IL-13\u2013OVOL1\u2013FLG axis in atopic dermatitis. Immunology. 2019;158:281\u20136. https:\/\/doi.org\/10.1111\/imm.13120.","journal-title":"Immunology"},{"key":"1048_CR76","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37:1046\u201355. https:\/\/doi.org\/10.1111\/jdv.18849.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1048_CR77","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1159\/000519361","volume":"238","author":"A Chiricozzi","year":"2022","unstructured":"Chiricozzi A, Gori N, Di Nardo L, et al. Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients. Dermatology. 2022;238:717\u201324. https:\/\/doi.org\/10.1159\/000519361.","journal-title":"Dermatology"},{"issue":"1","key":"1048_CR78","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamadermatol.2025.3986","volume":"162","author":"R Zhang","year":"2026","unstructured":"Zhang R, Wan J. Topical anti-inflammatory treatments for atopic dermatitis. JAMA Dermatol. 2026;162(1):80\u20132. https:\/\/doi.org\/10.1001\/jamadermatol.2025.3986.","journal-title":"JAMA Dermatol"},{"key":"1048_CR79","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","volume":"152","author":"DK Chu","year":"2023","unstructured":"Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152:1493\u2013519. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.030.","journal-title":"J Allergy Clin Immunol"},{"key":"1048_CR80","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12016-024-09000-7","volume":"66","author":"AC Chong","year":"2024","unstructured":"Chong AC, Navarro-Trivi\u00f1o F, Su M, Park CO. Fungal head and neck dermatitis: current understanding and management. Clin Rev Allergy Immunol. 2024;66:363\u201375. https:\/\/doi.org\/10.1007\/s12016-024-09000-7.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1048_CR81","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40257-018-0370-9","volume":"19","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Blair HA. Dupilumab: a review in moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2018;19:617\u201324. https:\/\/doi.org\/10.1007\/s40257-018-0370-9.","journal-title":"Am J Clin Dermatol"},{"key":"1048_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1705374","author":"Z Li","year":"2025","unstructured":"Li Z, Peng J, Yu R, et al. Real-world efficacy and safety of dupilumab in the treatment of head and neck atopic dermatitis: a retrospective cohort study. Front Med (Lausanne). 2025. https:\/\/doi.org\/10.3389\/fmed.2025.1705374.","journal-title":"Front Med (Lausanne)"},{"key":"1048_CR83","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/ijd.70116","volume":"65","author":"MC Fialho","year":"2026","unstructured":"Fialho MC, Figueira Vilela B, Sim\u00f5es FP. Characterization and management of dupilumab-associated head and neck dermatitis: experience of a tertiary center. Int J Dermatol. 2026;65:842\u20137. https:\/\/doi.org\/10.1111\/ijd.70116.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1048_CR84","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/ced\/llaf441","volume":"51","author":"M D\u2019Agostino","year":"2026","unstructured":"D\u2019Agostino M, Potestio L, Patruno C, et al. The use of dupilumab in difficult-to-treat areas of atopic dermatitis: lessons from real-world Studies. Clin Exp Dermatol. 2026;51(2):202\u201311. https:\/\/doi.org\/10.1093\/ced\/llaf441.","journal-title":"Clin Exp Dermatol"},{"key":"1048_CR85","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaad.2021.06.017","volume":"86","author":"S Narla","year":"2022","unstructured":"Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86:628\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.017.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR86","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ajd.14264","volume":"65","author":"FJ Navarro-Trivi\u00f1o","year":"2024","unstructured":"Navarro-Trivi\u00f1o FJ, Salazar-Nievas M, Sanz-Cabanillas JL, et al. Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: a multicentre study of 12 patients. Australas J Dermatol. 2024;65:260\u20135. https:\/\/doi.org\/10.1111\/ajd.14264.","journal-title":"Australas J Dermatol"},{"key":"1048_CR87","doi-asserted-by":"publisher","first-page":"171035682513632","DOI":"10.1177\/17103568251363249","volume":"30","author":"G Avallone","year":"2025","unstructured":"Avallone G, Valtellini L, Tavoletti G, et al. Effectiveness of tralokinumab for moderate-to-severe atopic dermatitis involving the head-and-neck area: a multicenter retrospective cohort study. Dermatitis. 2025;30:17103568251363248. https:\/\/doi.org\/10.1177\/17103568251363249.","journal-title":"Dermatitis"},{"key":"1048_CR88","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40257-025-00931-1","volume":"26","author":"R Chovatiya","year":"2025","unstructured":"Chovatiya R, Ribero S, Wollenberg A, et al. Long-term disease control and minimal disease activity of head and neck atopic dermatitis in patients treated with tralokinumab up to 4 years. Am J Clin Dermatol. 2025;26:587\u2013601. https:\/\/doi.org\/10.1007\/s40257-025-00931-1.","journal-title":"Am J Clin Dermatol"},{"key":"1048_CR89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14712598.2024.2435427","volume":"25","author":"L Stingeni","year":"2025","unstructured":"Stingeni L, Ferrucci S, Amerio P, et al. Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis. Expert Opin Biol Ther. 2025;25:15\u201320. https:\/\/doi.org\/10.1080\/14712598.2024.2435427.","journal-title":"Expert Opin Biol Ther"},{"key":"1048_CR90","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","volume":"425","author":"M Ultsch","year":"2013","unstructured":"Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J Mol Biol. 2013;425:1330\u20139. https:\/\/doi.org\/10.1016\/j.jmb.2013.01.024.","journal-title":"J Mol Biol"},{"key":"1048_CR91","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2492188","author":"JE Murase","year":"2025","unstructured":"Murase JE, Eyerich K, Chovatiya R, et al. Lebrikizumab improves head\/neck\/face dermatitis and erythema and does not increase treatment-emergent adverse events of head\/neck\/face erythema in patients with moderate-to-severe atopic dermatitis. J Dermatol Treat. 2025. https:\/\/doi.org\/10.1080\/09546634.2025.2492188.","journal-title":"J Dermatol Treat"},{"issue":"5","key":"1048_CR92","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s13555-026-01726-w","volume":"16","author":"L Gargiulo","year":"2026","unstructured":"Gargiulo L, Ibba L, Bianco M, et al. Real-world effectiveness and safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: a 52-week retrospective Italian study focusing on head and neck involvement. Dermatol Ther (Heidelb). 2026;16(5):2499\u2013512. https:\/\/doi.org\/10.1007\/s13555-026-01726-w.","journal-title":"Dermatol Ther. (Heidelb)"},{"issue":"5","key":"1048_CR93","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/1346-8138.70183","volume":"53","author":"M Shiba","year":"2026","unstructured":"Shiba M, Hagino T, Uchiyama A, et al. Effectiveness of anti-IL-13 antibodies on head and neck lesions in atopic dermatitis: 48-week outcomes by lebrikizumab and tralokinumab. J Dermatol. 2026;53(5):780\u20138. https:\/\/doi.org\/10.1111\/1346-8138.70183.","journal-title":"J Dermatol"},{"key":"1048_CR94","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000542275","volume":"241","author":"JP Thyssen","year":"2025","unstructured":"Thyssen JP, Rosmarin D, Costanzo A, et al. Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: analysis from the Heads Up Study. Dermatology. 2025;241:10\u20138. https:\/\/doi.org\/10.1159\/000542275.","journal-title":"Dermatology"},{"issue":"2","key":"1048_CR95","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jaad.2025.08.085","volume":"94","author":"W Ting-yu","year":"2026","unstructured":"Ting-yu W, Zheng-hui Y, Ying T, et al. Efficacy of abrocitinib in patients with moderate-to-severe head and neck dermatitis. J Am Acad Dermatol. 2026;94(2):576\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.085.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR96","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1684\/ejd.2022.4280","volume":"32","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Lio P, Kleyn E, et al. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five phase III clinical trials. Eur J Dermatol. 2022;32:522\u20139. https:\/\/doi.org\/10.1684\/ejd.2022.4280.","journal-title":"Eur J Dermatol"},{"key":"1048_CR97","doi-asserted-by":"publisher","first-page":"s5","DOI":"10.36849\/JDD.49142","volume":"24","author":"NT Issa","year":"2025","unstructured":"Issa NT, Kwong P, Bunick CG, Kircik L. Appraisal of ruxolitinib 1.5% cream as a first-line topical therapeutic agent for adolescents and adults with mild-to-moderate atopic dermatitis. J Drugs Dermatol. 2025;24:s5-15. https:\/\/doi.org\/10.36849\/JDD.49142.","journal-title":"J Drugs Dermatol"},{"key":"1048_CR98","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85:863\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR99","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2480744","author":"ZC Chiesa Fuxench","year":"2025","unstructured":"Chiesa Fuxench ZC, Lai Z, Kuo Y, et al. Ruxolitinib cream monotherapy for facial and\/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial. J Dermatol Treat. 2025. https:\/\/doi.org\/10.1080\/09546634.2025.2480744.","journal-title":"J Dermatol Treat"},{"key":"1048_CR100","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40257-022-00748-2","volume":"24","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Ruxolitinib cream 1.5%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2023;24:143\u201351. https:\/\/doi.org\/10.1007\/s40257-022-00748-2.","journal-title":"Am J Clin Dermatol"},{"key":"1048_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","author":"I-H Huang","year":"2022","unstructured":"Huang I-H, Chung W-H, Wu P-C, Chen C-B. JAK\u2013STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1068260.","journal-title":"Front Immunol"},{"key":"1048_CR102","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2310633","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Bissonnette R, Chiesa Fuxench ZC. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies. J Dermatol Treat. 2024. https:\/\/doi.org\/10.1080\/09546634.2024.2310633.","journal-title":"J Dermatol Treat"},{"key":"1048_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.620098","author":"MD Scuron","year":"2021","unstructured":"Scuron MD, Fay BL, Connell AJ, et al. Ruxolitinib cream has dual efficacy on pruritus and inflammation in experimental dermatitis. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2020.620098.","journal-title":"Front Immunol"},{"key":"1048_CR104","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70132","author":"LF Koh","year":"2025","unstructured":"Koh LF, Firdaus MJ, Natsuaki Y, et al. Ruxolitinib alleviates inflammation and fortifies skin barrier function through dampening IL-13. Exp Dermatol. 2025. https:\/\/doi.org\/10.1111\/exd.70132.","journal-title":"Exp Dermatol"},{"key":"1048_CR105","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Delgocitinib: first approval. Drugs. 2020;80:609\u201315. https:\/\/doi.org\/10.1007\/s40265-020-01291-2.","journal-title":"Drugs"},{"key":"1048_CR106","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/1346-8138.17817","volume":"52","author":"M Abe","year":"2025","unstructured":"Abe M, Igarashi A, Kitajima H, et al. Treatment satisfaction, efficacy, and safety of delgocitinib ointment for atopic dermatitis-induced rash on the face and neck: efficacy at reducing local side effects of topical steroid and tacrolimus ointment. J Dermatol. 2025;52:1232\u201342. https:\/\/doi.org\/10.1111\/1346-8138.17817.","journal-title":"J Dermatol"},{"key":"1048_CR107","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15526","author":"M Suehiro","year":"2022","unstructured":"Suehiro M, Numata T, Murakami E, et al. Real-world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15526.","journal-title":"Dermatol Ther"},{"key":"1048_CR108","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91:457\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.023.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR109","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","volume":"160","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children. JAMA Dermatol. 2024;160:1161. https:\/\/doi.org\/10.1001\/jamadermatol.2024.3121.","journal-title":"JAMA Dermatol"},{"key":"1048_CR110","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/cells13070587","volume":"13","author":"K Sadrolashrafi","year":"2024","unstructured":"Sadrolashrafi K, Guo L, Kikuchi R, et al. An OX-Tra\u2019Ordinary tale: the role of OX40 and OX40L in atopic dermatitis. Cells. 2024;13:587. https:\/\/doi.org\/10.3390\/cells13070587.","journal-title":"Cells"},{"key":"1048_CR111","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.3390\/jcm13226925","volume":"13","author":"M Marfil-Cant\u00f3n","year":"2024","unstructured":"Marfil-Cant\u00f3n M, Prados-Carmona A, Cebolla-Verdugo M, et al. Anti-OX40 biological therapies in the treatment of atopic dermatitis: a comprehensive review. J Clin Med. 2024;13:6925. https:\/\/doi.org\/10.3390\/jcm13226925.","journal-title":"J Clin Med"},{"key":"1048_CR112","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Simpson EL, Reich K, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023;401:204\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(22)02037-2.","journal-title":"Lancet"},{"key":"1048_CR113","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Blauvelt A, Papp KA, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025;155:1264\u201375. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.031.","journal-title":"J Allergy Clin Immunol"},{"key":"1048_CR114","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C, et al. OX40 in the pathogenesis of atopic dermatitis: a new therapeutic target. Am J Clin Dermatol. 2024;25:447\u201361. https:\/\/doi.org\/10.1007\/s40257-023-00838-9.","journal-title":"Am J Clin Dermatol"},{"key":"1048_CR115","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03426-x","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Esfandiari E, Mano H, et al. Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab. Arch Dermatol Res. 2024. https:\/\/doi.org\/10.1007\/s00403-024-03426-x.","journal-title":"Arch Dermatol Res"},{"key":"1048_CR116","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","volume":"84","author":"JM Alvarenga","year":"2024","unstructured":"Alvarenga JM, Bieber T, Torres T. Emerging biologic therapies for the treatment of atopic dermatitis. Drugs. 2024;84:1379\u201394. https:\/\/doi.org\/10.1007\/s40265-024-02095-4.","journal-title":"Drugs"},{"key":"1048_CR117","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaci.2025.05.007","volume":"156","author":"LD Meesters","year":"2025","unstructured":"Meesters LD, Roubroeks JAY, Gerritsen A, et al. Dissecting key contributions of TH2 and TH17 cytokines to atopic dermatitis pathophysiology. J Allergy Clin Immunol. 2025;156:690\u2013704. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.007.","journal-title":"J Allergy Clin Immunol"},{"key":"1048_CR118","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","volume":"86","author":"DMR Davis","year":"2022","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. American Academy of Dermatology guidelines: awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022;86:1335-6.e18. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.009.","journal-title":"J Am Acad Dermatol"},{"key":"1048_CR119","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15094","volume":"8","author":"AR Sitarik","year":"2025","unstructured":"Sitarik AR, Eapen AA, Biagini JM, et al. Phenotypes of atopic dermatitis and development of allergic diseases. JAMA Netw Open. 2025;8:e2515094. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15094.","journal-title":"JAMA Netw Open"},{"key":"1048_CR120","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1744666X.2020.1858802","volume":"17","author":"C Tubau","year":"2021","unstructured":"Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol. 2021;17:15\u201325. https:\/\/doi.org\/10.1080\/1744666X.2020.1858802.","journal-title":"Expert Rev Clin Immunol"},{"key":"1048_CR121","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241286832","author":"C Teixeira","year":"2024","unstructured":"Teixeira C, Yilmaz O, Bernardo D, Torres T. IL-13 inhibition in the treatment of atopic dermatitis: new and emerging biologic agents. J Int Med Res. 2024. https:\/\/doi.org\/10.1177\/03000605241286832.","journal-title":"J Int Med Res"},{"key":"1048_CR122","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jaip.2025.04.042","volume":"13","author":"M Kamata","year":"2025","unstructured":"Kamata M, Sun DI, Paller AS. Deciding which patients with atopic dermatitis to prioritize for biologics and Janus kinase inhibitors. J Allergy Clin Immunol Pract. 2025;13:1901-10.e1. https:\/\/doi.org\/10.1016\/j.jaip.2025.04.042.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1048_CR123","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/exd.14753","volume":"32","author":"S Sadeghi","year":"2023","unstructured":"Sadeghi S, Mohandesi NA. Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: a systematic review. Exp Dermatol. 2023;32:599\u2013610. https:\/\/doi.org\/10.1111\/exd.14753.","journal-title":"Exp Dermatol"},{"key":"1048_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70161","author":"M Xie","year":"2025","unstructured":"Xie M, Kong L, Li G, et al. Atopic dermatitis: updated insights into pathophysiology and emerging therapies. Drug Dev Res. 2025. https:\/\/doi.org\/10.1002\/ddr.70161.","journal-title":"Drug Dev Res"},{"key":"1048_CR125","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.anai.2025.06.020","volume":"135","author":"K Gallagher","year":"2025","unstructured":"Gallagher K, Halperin-Goldstein S, Paller AS. New treatments in atopic dermatitis update. Ann Allergy Asthma Immunol. 2025;135:498-510.e10. https:\/\/doi.org\/10.1016\/j.anai.2025.06.020.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1048_CR126","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405:583\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(24)02519-4.","journal-title":"Lancet"},{"key":"1048_CR127","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40257-026-01013-6","volume":"27","author":"EM Stevens","year":"2026","unstructured":"Stevens EM, Vester-Glowinski K, Skov L, et al. Effectiveness of systemic treatments for atopic dermatitis in the head-and-neck-area: a systematic review and meta-analysis. Am J Clin Dermatol. 2026;27:277\u201395. https:\/\/doi.org\/10.1007\/s40257-026-01013-6.","journal-title":"Am J Clin Dermatol"},{"key":"1048_CR128","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/antib14040104","volume":"14","author":"G Lauletta","year":"2025","unstructured":"Lauletta G, Patruno C, Brescia C, et al. Head and neck dermatitis in atopic dermatitis: a narrative review of pathogenesis, clinical challenges, and therapeutic strategies. Antibodies. 2025;14:104. https:\/\/doi.org\/10.3390\/antib14040104.","journal-title":"Antibodies"},{"key":"1048_CR129","unstructured":"Incyte Corporation. Ruxolitinib cream monotherapy for facial and\/or neck atopic dermatitis [NCT05127421]. ClinicalTrials.gov. ClinicalTrials.gov NCT05127421. Accessed 26 May 2026."},{"key":"1048_CR130","unstructured":"Arcutis Biotherapeutics. Study to evaluate the efficacy and safety of roflumilast cream in participants with atopic dermatitis [NCT04804605]. ClinicalTrials.gov. ClinicalTrials.gov NCT04804605. Accessed 26 May 2026."},{"key":"1048_CR131","unstructured":"Sanofi. A study to assess the efficacy and safety of amlitelimab in participants aged 12 years and older with moderate-to-severe atopic dermatitis (OCEANA) [NCT06181435]. ClinicalTrials.gov. ClinicalTrials.gov NCT06181435. Accessed 26 May 2026."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01048-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01048-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01048-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:32:11Z","timestamp":1789464731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01048-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":131,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01048-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Francisco Jos\u00e9 Navarro-Trivi\u00f1o, Ricardo Ruiz-Villaverde, and Tiago Torres have no conflicts of interest that are directly relevant to the content of this article. Tiago Torres is an Editorial Board member of the\n                      American Journal of Clinical Dermatology\n                      . Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FJNT contributed to the study conception and design, drafting of the manuscript, and critical revision for important intellectual content; RRV contributed to the critical revision of the manuscript; and TT contributed to the critical revision of the manuscript. All authors approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}